Howard McLeod

Citée par

	Toutes	Depuis 2019
Citations	56635	15437
indice h	121	57
indice i10	503	283

3000

1500

750

2250

19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024199 309 429 731 909 1484 1681 2218 2250 2458 2359 2568 2698 2907 2882 2976 2877 2719 2716 2692 2813 2817 2941 2673 2391 1790

Accès public

Tout afficher

192 articles

31 articles

disponibles

non disponibles

Sur la base des exigences liées au financement

Coauteurs

Teri E. KleinStanford UniversityAdresse e-mail validée de stanford.edu
Mark RatainLeon O. Jacobson Professor of Medicine, The University of ChicagoAdresse e-mail validée de uchicago.edu
Alison Motsinger-ReifNational Institute of Environmental Health SciencesAdresse e-mail validée de nih.gov
Richard Goldberg MDProfessor emeritus, West Virginia UniversityAdresse e-mail validée de hsc.wvu.edu
Mary V. RellingSt. Jude Children's Research HospitalAdresse e-mail validée de stjude.org
Daniel L HertzUniversity of MichiganAdresse e-mail validée de med.umich.edu
William E EvansSt. Jude Children's Research HospitalAdresse e-mail validée de stjude.org
Brian F. GageProfessor of Medicine, Washington University in St. LouisAdresse e-mail validée de im.wustl.edu
LISA A. CAREY MD, ScM, FASCOUniversity of North Carolina Lineberger Comprehensive Cancer CenterAdresse e-mail validée de med.unc.edu
Russ B AltmanProfessor Stanford UniversityAdresse e-mail validée de stanford.edu
Deepak VooraDepartment of Veterans Affairs; Duke University Medical CenterAdresse e-mail validée de duke.edu
Jai N. Patel, PharmD, BCOP, CPPChair, Cancer Pharmacology & Pharmacogenomics, Levine Cancer Institute, Atrium HealthAdresse e-mail validée de atriumhealth.org
Todd C. KnepperAssociate Member, Precision Medicine, Moffitt Cancer CenterAdresse e-mail validée de moffitt.org
Jaap VerweijErasmus University Medical Center and Cancer Drug Development ForumAdresse e-mail validée de cddf.org
David E. LanfearHenry Ford HospitalAdresse e-mail validée de hfhs.org
David Ofori-AdjeiProfessor of Medicine & Therapeutics, University of GhanaAdresse e-mail validée de noguchi.ug.edu.gh
John SpertusSaint Luke's Mid America Heart Institute/University of Missouri - Kansas CityAdresse e-mail validée de umkc.edu
E Claire DeesUNCAdresse e-mail validée de med.unc.edu
Derek Van BoovenDirector Research Data, John P Hussman Insitute for Human Genomics, University of MiamiAdresse e-mail validée de med.miami.edu
Frank J. GonzalezNational Cancer InstituteAdresse e-mail validée de mail.nih.gov

Suivre

Howard McLeod

Utah Tech University

Adresse e-mail validée de utahtech.edu - Page d'accueil

personalized medicine cancer genomics Pharmacogenomics


Titre Trier par citations Trier par année Trier par titre	Citée par Citée par	Année
Pharmacogenomics—drug disposition, drug targets, and side effects WE Evans, HL McLeod New England journal of medicine 348 (6), 538-549, 2003	2511	2003
Doxorubicin pathways: pharmacodynamics and adverse effects CF Thorn, C Oshiro, S Marsh, T Hernandez-Boussard, H McLeod, ... Pharmacogenetics and genomics 21 (7), 440-446, 2011	1999	2011
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose MJ Rieder, AP Reiner, BF Gage, DA Nickerson, CS Eby, HL McLeod, ... New England Journal of Medicine 352 (22), 2285-2293, 2005	1840	2005
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin BF Gage, C Eby, JA Johnson, E Deych, MJ Rieder, PM Ridker, ... Clinical Pharmacology & Therapeutics 84 (3), 326-331, 2008	999	2008
Genomics and drug response L Wang, HL McLeod, RM Weinshilboum New England Journal of Medicine 364 (12), 1144-1153, 2011	762	2011
Platinum neurotoxicity pharmacogenetics SR McWhinney, RM Goldberg, HL McLeod Molecular cancer therapeutics 8 (1), 10-16, 2009	711	2009
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs S Zhou, SY Chan, BC Goh, E Chan, W Duan, M Huang, HL McLeod Clinical pharmacokinetics 44, 279-304, 2005	610	2005
MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity MM Ameyaw, F Regateiro, T Li, X Liu, M Tariq, A Mobarek, N Thornton, ... Pharmacogenetics and Genomics 11 (3), 217-221, 2001	608	2001
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update U Amstutz, LM Henricks, SM Offer, J Barbarino, JHM Schellens, JJ Swen, ... Clinical Pharmacology & Therapeutics 103 (2), 210-216, 2018	579	2018
UGT1A1* 28 genotype and irinotecan-induced neutropenia: dose matters JM Hoskins, RM Goldberg, P Qu, JG Ibrahim, HL McLeod Journal of the National Cancer Institute 99 (17), 1290-1295, 2007	578	2007
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer Y Wang, T Jatkoe, Y Zhang, MG Mutch, D Talantov, J Jiang, HL McLeod, ... Journal of clinical oncology 22 (9), 1564-1571, 2004	576	2004
PI3K/Akt/mTOR pathway as a target for cancer therapy D Morgensztern, HL McLeod Anti-cancer drugs 16 (8), 797-803, 2005	567	2005
Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia HL McLeod, EY Krynetski, MV Relling, WE Evans Leukemia 14 (4), 567-572, 2000	564	2000
Carbamazepine, HLA-B1502* and Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: US FDA Recommendations PB Ferrell, HL McLeod Pharmacogenomics 9 (10), 1543-1546, 2008	501	2008
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism GJ Peters, HHJ Backus, S Freemantle, B Van Triest, G Codacci-Pisanelli, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1587 (2-3 …, 2002	500	2002
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine AJ Black, HL McLeod, HA Capell, RH Powrie, LK Matowe, SC Pritchard, ... Annals of internal medicine 129 (9), 716-718, 1998	489	1998
Strategies for enzyme/prodrug cancer therapy G Xu, HL McLeod Clinical Cancer Research 7 (11), 3314-3324, 2001	480	2001
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. X Wei, HL McLeod, J McMurrough, FJ Gonzalez, P Fernandez-Salguero The Journal of clinical investigation 98 (3), 610-615, 1996	475	1996
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update LB Ramsey, SG Johnson, KE Caudle, CE Haidar, D Voora, RA Wilke, ... Clinical Pharmacology & Therapeutics 96 (4), 423-428, 2014	466	2014
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study JG Scott, A Berglund, MJ Schell, I Mihaylov, WJ Fulp, B Yue, E Welsh, ... The lancet oncology 18 (2), 202-211, 2017	461	2017

Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.

Articles 1–20

Nombre de citations par an

Citations en double

Citations fusionnées

Ajouter les coauteursCoauteurs

Suivre

Citée par

Coauteurs